| scholarly article | Q13442814 |
| P50 | author | Toshihiko Fujimori | Q39569662 |
| Yo-Ichi Nabeshima | Q123476420 | ||
| P2093 | author name string | Akiko Furuya | |
| Shinji Ito | |||
| Yoko Nabeshima | |||
| Junko Satoh | |||
| P2860 | cites work | Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis | Q24305561 |
| Mutation of the mouse klotho gene leads to a syndrome resembling ageing | Q24328782 | ||
| The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity | Q24630723 | ||
| A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION | Q25939000 | ||
| The enzymes, regulation, and genetics of bile acid synthesis | Q28204726 | ||
| Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP | Q28208653 | ||
| The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity | Q28219207 | ||
| Structures and mechanisms of glycosyl hydrolases | Q28271647 | ||
| Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha | Q28273937 | ||
| Role of nucleotide sequences of loxP spacer region in Cre-mediated recombination | Q28280406 | ||
| Mechanisms of enzymatic glycoside hydrolysis | Q28299677 | ||
| Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4 | Q28590891 | ||
| Regulation of the mevalonate pathway | Q29547763 | ||
| A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis | Q29617241 | ||
| Gallstones: an intestinal disease? | Q33534712 | ||
| Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis | Q33566678 | ||
| Gallstone formation. Local factors | Q33591428 | ||
| The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen | Q33899722 | ||
| Bile salt transporters: molecular characterization, function, and regulation | Q34186800 | ||
| Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion | Q34415865 | ||
| Bile salt transporters | Q34516267 | ||
| Cholic acid mediates negative feedback regulation of bile acid synthesis in mice | Q34785939 | ||
| Bile acid regulation of gene expression: roles of nuclear hormone receptors. | Q34803254 | ||
| Oral bile acid treatment of biliary cholesterol stones | Q35854870 | ||
| Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. | Q40743941 | ||
| Effect of bile on the intestinal bile-acid binding protein (I-BABP) expression. In vitro and in vivo studies | Q41205817 | ||
| Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway | Q43559873 | ||
| Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. | Q43759097 | ||
| Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression | Q43794445 | ||
| Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice | Q43852823 | ||
| Redundant pathways for negative feedback regulation of bile acid production | Q44025689 | ||
| A sharper image of SHP. | Q44085594 | ||
| Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice | Q44486153 | ||
| FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits | Q44535890 | ||
| Resistance of SHP-null mice to bile acid-induced liver damage | Q44559388 | ||
| Repression of cholesterol 7 alpha-hydroxylase transcription by bile acids is mediated through protein kinase C in primary cultures of rat hepatocytes | Q45082696 | ||
| Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids | Q45305228 | ||
| Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. | Q52163868 | ||
| Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. | Q52541251 | ||
| The relation between formation of gallstones rich in cholesterol and the solubility of cholesterol in aqueos solutions of bile salts and lecithin | Q71853280 | ||
| Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription | Q73615958 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2202-2208 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho | |
| P478 | volume | 115 |
| Q35028313 | A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea |
| Q53233233 | A nontumorigenic variant of FGF19 treats cholestatic liver diseases. |
| Q35942523 | A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways |
| Q43072181 | A sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid/base residues in human retaining β-glucosidases. |
| Q36342875 | Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho |
| Q54352759 | Assessment of matrix Gla protein, Klotho gene polymorphisms, and oxidative stress in chronic kidney disease. |
| Q24681531 | BetaKlotho is required for metabolic activity of fibroblast growth factor 21 |
| Q82068721 | BetaKlotho: a new kid on the bile acid biosynthesis block |
| Q26800206 | Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer |
| Q35737058 | Bile Acids as Hormones: The FXR-FGF15/19 Pathway |
| Q38198859 | Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy |
| Q27002873 | Bile acid metabolism and signaling |
| Q57128781 | Bile acid receptors link nutrient sensing to metabolic regulation |
| Q26822467 | Bile acids are nutrient signaling hormones |
| Q27022441 | Bile acids as metabolic regulators |
| Q37297846 | Bile acids as regulatory molecules |
| Q24658139 | Bile acids: regulation of synthesis |
| Q26777149 | Biological Role of Anti-aging Protein Klotho |
| Q24317949 | C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors |
| Q38723347 | Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action |
| Q55052281 | Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. |
| Q24603434 | Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release |
| Q34665759 | Co-receptor requirements for fibroblast growth factor-19 signaling |
| Q41873388 | Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress |
| Q34258918 | Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations |
| Q46689944 | Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. |
| Q39374896 | Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. |
| Q36472485 | Discovery of alpha-Klotho unveiled new insights into calcium and phosphate homeostasis |
| Q49298283 | Downregulation of klotho β is associated with invasive ductal carcinoma progression |
| Q40277667 | Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy. |
| Q36646646 | Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease |
| Q38023300 | Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. |
| Q24629260 | Endocrine fibroblast growth factors 15/19 and 21: from feast to famine |
| Q35027404 | Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis |
| Q90173858 | Evaluation of a cell model expressing βKlotho for screening FGF21 analogues |
| Q37318049 | Extracellular interactome of the FGF receptor-ligand system: complexities and the relative simplicity of the worm |
| Q47183309 | FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia |
| Q42176870 | FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology |
| Q36415805 | FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho |
| Q38305576 | Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. |
| Q38880909 | Fgf21 regulates T-cell development in the neonatal and juvenile thymus |
| Q36796145 | Fibroblast growth factor 21 mediates specific glucagon actions |
| Q36477896 | Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians |
| Q30544587 | Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism |
| Q35020888 | Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease |
| Q37278814 | Fifty years of advances in bile acid synthesis and metabolism |
| Q50163355 | Functions of the Gallbladder |
| Q57109437 | Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21 |
| Q24294403 | Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1 |
| Q36623086 | Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity |
| Q50459213 | Histochemical Examination on Periodontal Tissues of Klotho-Deficient Mice Fed With Phosphate-Insufficient Diet |
| Q37781747 | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease |
| Q41889886 | KLB, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism |
| Q37591992 | Klotho |
| Q50235923 | Klotho May Ameliorate Proteinuria by Targeting TRPC6 Channels in Podocytes. |
| Q24654902 | Klotho and aging |
| Q35033538 | Klotho and the aging process |
| Q37051351 | Klotho as a regulator of oxidative stress and senescence |
| Q28272505 | Klotho converts canonical FGF receptor into a specific receptor for FGF23 |
| Q35991812 | Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma |
| Q24319088 | Liver-specific activities of FGF19 require Klotho beta |
| Q42110387 | Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice |
| Q97643831 | Metabolic Messengers: fibroblast growth factor 15/19 |
| Q36746670 | Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis |
| Q39676210 | Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation |
| Q37160100 | MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity |
| Q36739805 | MicroRNAs in Liver Health and Disease |
| Q35441666 | Molecular basis of Klotho: from gene to function in aging |
| Q24683254 | Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members |
| Q42622908 | Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism |
| Q36987335 | Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules |
| Q36843966 | Pleiotropic roles of bile acids in metabolism |
| Q55518318 | Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. |
| Q57147768 | Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation |
| Q35836340 | Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis |
| Q28587100 | Regulation of fibroblast growth factor-23 signaling by klotho |
| Q33667883 | Relevant use of Klotho in FGF19 subfamily signaling system in vivo |
| Q36417890 | Renal Production, Uptake, and Handling of Circulating αKlotho |
| Q34197301 | Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. |
| Q41974026 | Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis |
| Q28072691 | Roles of FGF Signals in Heart Development, Health, and Disease |
| Q57294546 | Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications |
| Q37303131 | Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice |
| Q42130842 | Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients |
| Q38781182 | Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis |
| Q37569266 | Sterol regulation of metabolism, homeostasis, and development |
| Q36845708 | Structure and function of the atypical orphan nuclear receptor small heterodimer partner |
| Q42133073 | Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation |
| Q38176101 | Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations |
| Q37231731 | Targeting bile-acid signalling for metabolic diseases |
| Q36933339 | The FGF family: biology, pathophysiology and therapy |
| Q35001264 | The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling |
| Q93222971 | The Klotho proteins in health and disease |
| Q34568579 | The cooperation of FGF receptor and Klotho is involved in excretory canal development and regulation of metabolic homeostasis in Caenorhabditis elegans. |
| Q36992839 | The role of Klotho in energy metabolism |
| Q36928572 | The structural biology of the FGF19 subfamily |
| Q38633258 | Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. |
| Q34778879 | Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. |
| Q24318639 | Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 |
| Q42928079 | Weaving betaKlotho into bile acid metabolism |
| Q36977082 | beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes |
| Q24306279 | betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c |
| Q37575666 | c-Fos mediates repression of the apical sodium-dependent bile acid transporter by fibroblast growth factor-19 in mice |
| Q33578966 | β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. |
| Q36248720 | βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism |
| Q34576805 | βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway |
Search more.